- Home
- MDBH vs VYNE Comparison
MDBH vs VYNE Comparison
Compare MDBH & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDBH
- VYNE
- Stock Information
- Founded
- MDBH 1997
- VYNE 2003
- Country
- MDBH United States
- VYNE United States
- Employees
- MDBH N/A
- VYNE N/A
- Industry
- MDBH
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- MDBH
- VYNE Health Care
- Exchange
- MDBH Nasdaq
- VYNE Nasdaq
- Market Cap
- MDBH 39.3M
- VYNE 35.7M
- IPO Year
- MDBH 2023
- VYNE 2018
- Fundamental
- Price
- MDBH $3.80
- VYNE $0.95
- Analyst Decision
- MDBH
- VYNE Strong Buy
- Analyst Count
- MDBH 0
- VYNE 2
- Target Price
- MDBH N/A
- VYNE $6.25
- AVG Volume (30 Days)
- MDBH 6.0K
- VYNE 259.3K
- Earning Date
- MDBH 05-12-2025
- VYNE 05-08-2025
- Dividend Yield
- MDBH N/A
- VYNE N/A
- EPS Growth
- MDBH N/A
- VYNE N/A
- EPS
- MDBH 0.84
- VYNE N/A
- Revenue
- MDBH $3,574,131.00
- VYNE $605,000.00
- Revenue This Year
- MDBH N/A
- VYNE N/A
- Revenue Next Year
- MDBH N/A
- VYNE N/A
- P/E Ratio
- MDBH $4.51
- VYNE N/A
- Revenue Growth
- MDBH N/A
- VYNE 43.03
- 52 Week Low
- MDBH $3.61
- VYNE $0.95
- 52 Week High
- MDBH $12.00
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- MDBH 33.72
- VYNE 25.56
- Support Level
- MDBH $4.08
- VYNE $0.96
- Resistance Level
- MDBH $5.06
- VYNE $1.09
- Average True Range (ATR)
- MDBH 0.23
- VYNE 0.09
- MACD
- MDBH -0.04
- VYNE -0.01
- Stochastic Oscillator
- MDBH 13.10
- VYNE 0.00
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.